🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

8,395 results for “La” Clear

  1. Abrocitinib Placebo, Abrocitinib

    Pfizer Australia Pty Ltd

    Moderate-to-Severe Atopic Dermatitis

    phase 3 small molecule active

    1 trial

  2. Acalabrutinib

    AstraZeneca

    Untreated Chronic Lymphocytic Leukemia

    phase 3 small molecule active

    1 trial

  3. Acetadote EF (Ethylenediaminetetraacetic Acid (EDTA) - Free)

    CUMBERLAND PHARMACEUTICALS INC

    Acetaminophen Overdose

    phase 3 small molecule terminated

    1 trial

  4. Acetazolamide Levamisole

    The First People's Hospital of Lianyungang

    HCC

    phase 3 small molecule active

    1 trial

  5. Acnatac 10mg/g + 0,25mg/g Gel, Clindamycin Tretinoin Gel, Vehicle to Clindamycin Tretinoin Gel

    Alphapharm Pty Ltd

    Papulopustular acne

    phase 3 small molecule active

    1 trial

  6. Acoramidis

    BridgeBio Oncology Therapeutics

    Transthyretin-Related (ATTR) Familial Amyloid Polyneuropathy

    phase 3 small molecule terminated

    1 trial

  7. Acoramidis (AG10)

    BridgeBio Oncology Therapeutics

    Amyloid Cardiomyopathy, Transthyretin-Related

    phase 3 small molecule active

    1 trial

  8. Actilyse, polvo y disolvente para solución inyectable y para perfusión, Actilyse, polvo y disolvente para solución inyectable y para perfusión

    The George Institute

    People with acute ischemic stroke (AIS) due to large vessel occlusion of the anterior circulation.

    phase 3 small molecule active

    1 trial

  9. Active

    Aclaris Therapeutics

    Common Wart

    phase 3 small molecule completed

    1 trial

  10. Active Surveillance

    Blackmores Limited

    Muscle-Invasive Bladder Carcinoma

    phase 3 other active

    1 trial

  11. Adjuvant Immunomodulatory (IM) Therapy

    Ultragenyx UK Limited

    Mucopolysaccharidosis IIIA

    phase 3 small molecule active

    1 trial

  12. Adtralza 150 mg solution for injection in pre-filled syringe, The placebo presentation is a pre-filled syringe containing the same excipients in the same amounts as the IMP.

    LEO Pharma A/S

    Treatment of moderate-to-severe Atopic dermatitis

    phase 3 small molecule active

    1 trial

  13. Afatinib

    Boehringer Ingelheim

    Head and Neck Neoplasms

    phase 3 small molecule completed

    1 trial

  14. Aficamten, Tablet placebo for aficamten 5mg tablet

    Cytokinetics (Ireland) Limited

    SYMPTOMATIC OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY

    phase 3 small molecule active

    1 trial

  15. Afimkibart

    Hoffmann-La Roche

    Moderately to Severely Active Crohns Disease

    phase 3 small molecule active

    1 trial

  16. Afinitor 5 mg tablets, PLACEBO

    Ningbo Cancer Hospital

    Patients with high risk of relapse, ER+ and HER2- primary non-metastatic breast cancer who remain disease-free

    phase 3 small molecule active

    1 trial

  17. Aflibercept

    Regeneron UK Limited

    Prostatic Neoplasms

    phase 3 small molecule completed

    1 trial

  18. Aflibercept

    Hoffmann-La Roche

    Diabetic Macular Edema

    phase 3 small molecule completed

    1 trial

  19. Aflibercept (EYLEA, BAY86-5321)

    Regeneron UK Limited

    Glaucoma, Neovascular

    phase 3 small molecule completed

    1 trial

  20. Aflibercept (Eylea, BAY 86-5321)

    Regeneron UK Limited

    Glaucoma, Neovascular

    phase 3 small molecule completed

    1 trial

  21. Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)

    Regeneron UK Limited

    Macular Degeneration

    phase 3 mab completed

    1 trial

  22. Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)

    Regeneron UK Limited

    Macular Edema

    phase 3 mab completed

    1 trial

  23. Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)

    Bayer HealthCare AG

    Macular Edema

    phase 3 mab completed

    1 trial

  24. Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)

    Regeneron UK Limited

    Pancreatic Neoplasm

    phase 3 small molecule terminated

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources